亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        SARS-CoV-2 infection in liver transplant recipients: A complex relationship

        2021-12-04 23:19:01RicardoWesleyAlbercaGilBenardGabrielaGamaFreireAlbercaMariaNotomiSato
        World Journal of Gastroenterology 2021年44期

        Ricardo Wesley Alberca, Gil Benard, Gabriela Gama Freire Alberca, Maria Notomi Sato

        Abstract The recent manuscript reviewed investigations involving liver damage in coronavirus disease 2019 (COVID-19 ) patients, and COVID-19 in patients with previous chronic hepatological diseases, such as patients with liver graft. The literature presents several conflicting results concerning the anti-SARS-CoV-2 response in patients with solid organ transplants, in liver transplant recipients.Therefore, we would like to humbly state a few points for consideration involving liver transplant recipients and COVID-19 , such as the time since transplantation,comorbidities, and immunosuppressive regimens.

        Key Words: COVID-19 ; SARS-CoV-2 ; Liver transplant; Immunosuppression; Infection;Comorbidities

        TO THE EDITOR

        We read with great interest the article entitled “Liver dysfunction and SARS-CoV-2 infection”, recently published by Gracia-Ramoset al[1 ] in the World Journal Gastroenterology[1 ]. Gracia-Ramos et al[1 ] performed a review on patients with liver dysfunction and coronavirus disease 2019 (COVID-19 ), highlighting investigations involving liver injury in COVID-19 patients, and COVID-19 in patients with previous chronic liver disease, such as cirrhosis and liver transplant recipients. Nevertheless, we would like to raise a few considerations regarding liver transplant recipients and COVID-19 .

        Transplantation is a treatment for organ failure and end-stage organ illnesses,requiring patients to undergo regular use of immunosuppressive treatment to avoid organ rejection[2 ]. There is no consensus regarding the increase in the incidence or severity of COVID-19 on solid organ transplant (SOT) recipients[3 ]. A few reports have identified an increase in severe COVID-19 and mortality rate in SOT recipients[4 ,5 ], while others failed to do so[3 ,6 ].

        SOT patients may respond differently to COVID-19 due to associated comorbidities,the organ grafted, elapsed time from the transplant surgery, drugs used to prevent organ rejection, or drugs used to treat SARS-CoV-2 infection[7 -9 ]. The identification of the organ grafted is usually described in the manuscripts[6 ], but only one manuscript with comparison between the different organ transplant recipients has been made so far, identifying an increase in mortality in kidney and heart transplant recipients in comparison to liver transplant recipients[5 ].

        A systematic review identified a similar death rate in liver transplant recipients and non-transplant recipients, but a higher percentage of non-transplant recipients were obese or had cardiovascular or respiratory diseases[10 ]. Hospitalization in the intensive care unit presented mixed results, and only one investigation reported the need for mechanical ventilation, and liver transplant recipients presented a greater need for it, in comparison to non-SOT patients[10 ]. Consequently, it is not possible to confirm if liver transplant recipients have a lower risk for severe illness or death risk in comparison to non-transplant recipients during COVID-19 .

        The liver allograft has a lower risk of rejection in comparison to heart and kidney allograft. Therefore, it is usually treated with reduced immunosuppressive regimens compared with the other SOT patients[11 ,12 ]. Different immunosuppressive regimens can affect the detection of SARS-CoV-2 RNA in nasopharyngeal swab tests[13 ].Tacrolimus, a commonly used drug by SOT patients, has been shown to display anticoronavirus effects in vitro[14 ] and putative protective properties in liver transplant recipients with COVID-19 [15 ]. In contrast, another report identified that tacrolimus has no significant effect on the mortality risk[16 ].

        We hypothesize that the inhibition of the calcineurin by tacrolimus could curb the production of proinflammatory cytokines, similarly to the observed in other inflammatory models[17 -19 ], and reduce or prevent the development of the cytokine storm in COVID-19 [20 ]. A recent report associated tacrolimus therapy with a protective effect in liver transplant recipients with COVID-19 [15 ]. Importantly, the use of tacrolimus in association with dexamethasone in immunocompetent COVID-19 patients is currently being tested in a Spanish clinical trial (clinicaltrials.gov/ct2 /show/NCT04341038 ).

        Importantly, SOT recipients (including liver, kidney, heart, lung, and others) have an increased risk of mortality due to infections in the first year after the transplant[21 ],especially respiratory infections[22 ]. A recent review identified a higher mortality rate in patients with over a year of organ draft[23 ]. Another report identified no difference in elapsed time from transplant in survival and non-survival COVID-19 patients, but patients presented a high incidence of other comorbidities[24 ]. In a recent report, liver transplant was not associated with greater mortality risk, while the association with other comorbidities (mainly diabetes, hypertension, obesity, and cardiovascular disease) posed a higher death risk[25 ]. It is reasonable to assume that comorbidities associated with poor outcomes in non-SOT patients will also influence the COVID-19 disease course in liver recipients, such as co-infection[26 ], respiratory disorders[27 ],and alcohol consumption[28 ]. In another report, liver transplant recipients presented similar mortality to non-SOT patients and reduced mortality in comparison with patients with liver cirrhosis[29 ].

        On the other hand, liver transplant recipients developed lower levels of anti-SARSCoV-2 IgG, and a more pronounced reduction in SARS-CoV-2 -specific IgG levels, 6 mo after COVID-19 [30 ]. Therefore, a long-term follow-up is necessary to fully determine the duration of the anti-SARS-CoV-2 immune response and the long-term protection offered by COVID-19 vaccines in liver transplant recipients. A recent report has identified SARS-CoV-2 infections in fully vaccinated SOT patients, and, importantly,the death of a fully vaccinated heart transplant patient due to COVID-19 [30 ].

        In conclusion, Gracia-Ramoset al[1 ] presented interesting points concerning liver transplant recipients with COVID-19 . However, further investigations are needed to better understand the impact of comorbidities, elapsed time since the organ transplant,immunosuppressive regimen, and vaccination on COVID-19 in liver transplant patients.

        精品国产a∨无码一区二区三区| 麻豆精品一区二区av白丝在线| 中文字幕亚洲精品无码| 亚洲精品一品区二品区三区| 国产综合在线观看| 日韩无码视频淫乱| 免费观看视频在线播放| 谷原希美中文字幕在线| 亚洲国产精品无码久久| 久久久久99精品国产片| 中文人妻av大区中文不卡| 日韩女优图播一区二区| 精品久久久久久无码中文字幕| 牛牛本精品99久久精品88m| 亚洲熟女国产熟女二区三区| 亚洲最新精品一区二区| 粗大的内捧猛烈进出视频| 亚洲午夜精品a区| 日韩女同一区二区三区久久| 国内精品免费一区二区三区| 日本丰满熟妇hd| 韩国一级成a人片在线观看| 亚洲成人av一区二区| 欧美激情在线播放| 成人片黄网站色大片免费观看app| 亚洲一区二区成人在线视频| 亚洲av少妇高潮喷水在线| 国产精品网站在线观看免费传媒 | 国产亚洲欧洲aⅴ综合一区| 一区二区传媒有限公司| 久久AV老司机精品网站导航| 免费国产在线精品三区| 中文字幕人妻少妇伦伦| 99久久精品日本一区二区免费 | 亚洲AV无码精品色午夜超碰| 日本女u久久精品视频| 初尝人妻少妇中文字幕| 粗大的内捧猛烈进出在线视频| 亚洲高清美女久久av| 亚洲国产精品久久久av| 色欲av亚洲一区无码少妇|